Perrigo Sets Strategy For Global Infant Formula Growth
This article was originally published in The Tan Sheet
Executive Summary
The private labeler’s more than 60 planned product launches include Codex-compliant infant formulas. The firm also sees marketing formula in plastic containers as a U.S. sales driver.
You may also be interested in...
Perrigo Eyes $115 Bil. Worth Of Rx-To-OTC Switches On The Horizon
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
Perrigo Grows Into Adjacent Infant Formula Category With PBM Acquisition
Perrigo takes the next step toward becoming a one-stop shop for private-label consumer health products with its $808 million acquisition of infant formula and baby food firm PBM Holdings Inc
No End To US FDA Concerns About DEG And EG Testing, Or To OTC Firms Not Answering Its Calls
One of firms targeted in eight most recent warnings published since early September to OTC drug manufacturers, Zhao Qing Longda Biotechnology Co. in China, was dinged for both failing to respond to a request for records and for concerns about its production with DEG and EG.